Skip to content

Study · Case report or series · n = 1 · 2026

2 results

Unexpected Residual Gastric Contents in a Patient After Holding Semaglutide After Standard Fasting Guidelines: A Case Report.

Ando K, Takenoshita M, Wei MT

A&A practice13 Feb 2026

PMID41705849 (opens in a new tab)DOI10.1213/xaa.0000000000002161 (opens in a new tab)PepBankPUB-41705849
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanCase report or seriesSafety outcome

    In a 58-year-old man on weekly semaglutide, substantial residual gastric contents remained despite fasting and withholding one dose, and the endoscopy was cancelled.

    In plain wordsOne man on semaglutide still had food in his stomach after fasting and skipping a dose, so his endoscopy was cancelled.

    Peptide
    Semaglutide
    Outcome
    Not applicableResidual gastric contents after withholding one weekly dose
    Study

    n = 1

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Despite these measures, substantial residual gastric contents led to procedure cancelation.
    1 context sentence
    Summary · context
    A 58-year-old man scheduled for an elective upper endoscopy followed standard preprocedural fasting guidelines and withheld one weekly dose of semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist (GLP-1 RA).
  2. 02HumanCase report or seriesSafety outcome

    At an earlier combined upper endoscopy and colonoscopy after withholding an identical weekly semaglutide dose, no residual gastric contents were observed in the same patient.

    In plain wordsThe same man had an empty stomach at an earlier procedure after skipping the same semaglutide dose.

    Peptide
    Semaglutide
    Outcome
    No significant changeResidual gastric contents at an earlier procedure after an identical dose hold
    Study

    n = 1

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Notably, the same patient previously underwent a combined upper endoscopy and colonoscopy after withholding an identical semaglutide weekly dose, with no residual gastric contents were observed.
    1 context sentence
    Summary · context
    A 58-year-old man scheduled for an elective upper endoscopy followed standard preprocedural fasting guidelines and withheld one weekly dose of semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist (GLP-1 RA).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.